Leman Biotech

Leman Biotech is a clinical-stage cancer immunotherapy company co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and XtalPi, a leader in AI-driven drug research and development. The company integrates innovative metabolic reprogramming technology with a cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies. Leman Biotech's Metabolic Reprogramming Technology (Meta 10) represents an innovative approach to combating T-cell exhaustion. Preclinical studies have demonstrated its ability to activate oxidative phosphorylation metabolism in terminally exhausted T cells, restoring their proliferative potential and cytotoxic activity. Promising results from these studies include effective tumor clearance in various mouse models and the induction of stem-like immune memory cells. In early 2023, Leman Biotech initiated an investigator-initiated clinical trial (IIT) for metabolically armed CD19 CAR-T therapy (Meta10-19 CAR-T) targeting patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) and acute B-lymphoblastic leukemia (r/r B-ALL). Remarkably, all patients treated with Meta10-19 CAR-T have achieved complete responses at low doses with minimal side effects. These findings highlight the immense clinical potential of Meta 10 technology. The company is headquartered in Shenzhen, a highly vibrant city with the highest number of start-ups per head of population in China, and established a research center in Lausanne Biopôle.